Reuters
2022.08.03 05:17

Sarepta Therapeutics Inc - QTRLY GAAP Net Loss Of $231.5 Million, Or $2.65 Per Basic And Diluted Share

Sarepta Therapeutics Inc:

Sarepta Therapeutics Inc (SRPT.O) :

  • SAREPTA THERAPEUTICS - INCREASED FULL-YEAR TOTAL REVENUE AND NET PRODUCT REVENUE GUIDANCE TO A RANGE OF $905-$920 MILLION AND $825-$840 MILLION, RESPECTIVELY

  • TOTAL REVENUES FOR Q2 2022 TOTALED $233.5 MILLION

  • QTRLY GAAP NET LOSS OF $231.5 MILLION, OR $2.65 PER BASIC AND DILUTED SHARE

  • QTRLY NON-GAAP NET LOSS $1.18 PER BASIC AND DILUTED SHARE

  • Q2 EARNINGS PER SHARE VIEW $-1.18, REVENUE VIEW $220.8 MILLION – REFINITIV IBES DATA

  • FY2022 REVENUE VIEW $899.9 MILLION – REFINITIV IBES DATA

The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: editorial@longbridge.global

Like